Examines V1bR's role in glucagon secretion and glucose regulation in α-cells, indicating significant implications for diabetes.
Introduction and Objective: Although hyperglucagonemia contributes to excessive hepatic glucose output and hyperglycemia in diabetes, many mechanisms that regulate glucagon secretion remain poorly understood. The Gq-coupled vasopressin 1b receptor (V1bR) is highly expressed in α-cells and activated by vasopressin (AVP), which is elevated in patients with type 2 diabetes. The objective of this study was to determine how α-cell V1bR contributes to glucagon secretion and glucose homeostasis. Methods: We generated an α-cell-specific V1bR knockdown mouse model using CRISPRi (αV1bR-KD). Plasma glucose and glucagon were measured after intraperitoneal glucose or 2-deoxy-D-glucose (2DG) injection. Glucagon secretion was also assessed using perifusion assays. Islet Ca2+ and cAMP dynamics were evaluated with dyes or genetically encoded indicators. Results: αV1bR-KD mice show improved glucose tolerance compared with α-Cre controls, demonstrated by decreased area under the curve (AUC, -5110±1950, P<0.05). Additionally, blocking glycolysis with 2DG caused reduced plasma glucagon in αV1bR-KD mice (-37.26±11.98 pM/L, P<0.05). V1bR activation enhanced α-cell Ca2+ influx in a glucose-dependent manner (11.22±1.82 AUC, P<0.01), leading to increased glucagon secretion in α-Cre control islets, whereas no effect was observed in αV1bR-KD islets (-0.7±0.1 AUC, P<0.01). The glucose dependence of V1bR signaling was dependent on SST signaling and blocked by SSTR2 inhibitors. V1bR-mediated glucagon secretion also caused paracrine stimulation of β-cell cAMP (3.0±0.5 AUC, P<0.01) and β-cell Ca2+ oscillation frequency (0.09±0.02 per minute, P<0.05). Conclusion: α-cell V1bR amplifies glucagon secretion during hypoglycemia and enhances α- to β-cell paracrine signaling but reduces glucose tolerance. These findings suggest that alterations in circulating AVP during the pathogenesis of diabetes may contribute to hyperglucagonemia and hyperglycemia.
No takes yet. Share an insight, caveat, or question.
GIBSON et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: